Ann: H1 2023 Preclinical and Clinical Programs Update, page-68

I had to "reassign" one of my GA tonight just for @pipjon but so many great contributions to the thread for this announcement.

Re EUR CDMO time will tell, expect a lot of speculation until the July/August strategic update but for the drug development moving preparing for commercialisation phase wouldn't be surprised if there was a collaboration/partnership (these take many forms, not just lambo buyouts) of sorts being worked out that needs to be announced at the right time. What are your thoughts @Boffin99 ?

Given the disadvantages of the standard of care central line CVC there should be a lot of interest from BP on the new formula & delivery pharmacokinetics.
Drug development trials is an area I need to revisit as I spent more time jumping ahead to the marketing modules instead.